NO20035160L - Anvendelse av IL-18 inhibitorer til å behandle eller forhindre CNS-skader - Google Patents

Anvendelse av IL-18 inhibitorer til å behandle eller forhindre CNS-skader

Info

Publication number
NO20035160L
NO20035160L NO20035160A NO20035160A NO20035160L NO 20035160 L NO20035160 L NO 20035160L NO 20035160 A NO20035160 A NO 20035160A NO 20035160 A NO20035160 A NO 20035160A NO 20035160 L NO20035160 L NO 20035160L
Authority
NO
Norway
Prior art keywords
inhibitors
treat
cns damage
prevent cns
prevent
Prior art date
Application number
NO20035160A
Other languages
English (en)
Other versions
NO331882B1 (no
NO20035160D0 (no
Inventor
Esther Shohami
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of NO20035160L publication Critical patent/NO20035160L/no
Publication of NO20035160D0 publication Critical patent/NO20035160D0/no
Publication of NO331882B1 publication Critical patent/NO331882B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO20035160A 2001-05-25 2003-11-20 Anvendelse av IL-18 inhibitorer til a behandle eller forhindre CNS-skader NO331882B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01112067 2001-05-25
PCT/EP2002/005666 WO2002096456A1 (en) 2001-05-25 2002-05-23 Use of il-18 inhibitors for treating or preventing cns injuries

Publications (3)

Publication Number Publication Date
NO20035160L true NO20035160L (no) 2003-11-20
NO20035160D0 NO20035160D0 (no) 2003-11-20
NO331882B1 NO331882B1 (no) 2012-04-23

Family

ID=8177454

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035160A NO331882B1 (no) 2001-05-25 2003-11-20 Anvendelse av IL-18 inhibitorer til a behandle eller forhindre CNS-skader

Country Status (30)

Country Link
US (1) US7655616B2 (no)
EP (1) EP1390070B1 (no)
JP (1) JP4344142B2 (no)
KR (1) KR20040030625A (no)
CN (1) CN1305529C (no)
AU (1) AU2002314103B2 (no)
BG (1) BG66395B1 (no)
BR (1) BR0210007A (no)
CA (1) CA2445664C (no)
CY (1) CY1119190T1 (no)
CZ (1) CZ307321B6 (no)
DK (1) DK1390070T3 (no)
EA (1) EA006744B1 (no)
EE (1) EE05263B1 (no)
ES (1) ES2617084T3 (no)
HK (1) HK1069762A1 (no)
HR (1) HRP20030842B1 (no)
HU (1) HU230294B1 (no)
IL (2) IL159014A0 (no)
LT (1) LT1390070T (no)
ME (1) ME00550B (no)
MX (1) MXPA03010743A (no)
NO (1) NO331882B1 (no)
PL (1) PL216228B1 (no)
PT (1) PT1390070T (no)
RS (1) RS56006B1 (no)
SK (1) SK288413B6 (no)
UA (1) UA80396C2 (no)
WO (1) WO2002096456A1 (no)
ZA (1) ZA200308172B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2524403C (en) 2003-05-13 2013-07-09 Applied Research Systems Ars Holding N.V. Active variants of the il-18 binding protein and medical uses thereof
US20090004683A1 (en) * 2004-06-30 2009-01-01 Atsuo Sekiyama Indicator Agent for Noninflammatory Stress Response and Use Thereof
US7691611B2 (en) 2005-06-03 2010-04-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
ES2376534T3 (es) * 2005-06-03 2012-03-14 Merck Serono Sa Uso de isoformas de il-18bp para el tratamiento y/o prevención de enfermedades inflamatorias neurológicas.
JP5091127B2 (ja) 2005-06-10 2012-12-05 アレス トレーディング ソシエテ アノニム Ｉｌ−１８結合タンパク質の精製のための方法
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
EP3978526A1 (en) * 2013-09-05 2022-04-06 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0873453A (ja) * 1994-09-02 1996-03-19 Otsuka Pharmaceut Co Ltd サイトカイン阻害剤
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
WO1999046248A1 (en) * 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CN1250286C (zh) * 2000-05-05 2006-04-12 应用研究系统Ars股份公司 Il－18抑制剂在治疗和/或预防动脉粥样硬化中的应用
DE60106026T2 (de) * 2000-06-23 2006-02-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag)-ein hemmer des tumor nekrose faktors-alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US6671553B1 (en) * 2001-05-23 2003-12-30 Pacesetter, Inc. Implantable cardiac lead having terminating connector strain relief and method of manufacture

Also Published As

Publication number Publication date
HRP20030842A2 (en) 2005-08-31
HK1069762A1 (en) 2005-06-03
AU2002314103B2 (en) 2007-07-12
US20040191247A1 (en) 2004-09-30
EA200301299A1 (ru) 2004-04-29
IL159014A (en) 2012-05-31
HUP0304067A3 (en) 2006-01-30
EP1390070A1 (en) 2004-02-25
CN1305529C (zh) 2007-03-21
ES2617084T3 (es) 2017-06-15
PL367545A1 (en) 2005-02-21
YU89403A (sh) 2006-05-25
EP1390070B1 (en) 2017-02-08
JP4344142B2 (ja) 2009-10-14
BG108451A (en) 2005-02-28
CA2445664C (en) 2012-03-06
MXPA03010743A (es) 2004-03-02
CA2445664A1 (en) 2002-12-05
LT1390070T (lt) 2017-03-10
ME00550B (me) 2011-10-10
CY1119190T1 (el) 2018-02-14
EE05263B1 (et) 2010-02-15
JP2004534777A (ja) 2004-11-18
WO2002096456A1 (en) 2002-12-05
NO331882B1 (no) 2012-04-23
BR0210007A (pt) 2004-08-10
BG66395B1 (bg) 2013-12-31
IL159014A0 (en) 2004-05-12
HRP20030842B1 (hr) 2017-06-02
HU230294B1 (hu) 2015-12-28
RS56006B1 (sr) 2017-09-29
PL216228B1 (pl) 2014-03-31
CZ20033268A3 (en) 2004-07-14
EE200300582A (et) 2004-02-16
EA006744B1 (ru) 2006-04-28
ZA200308172B (en) 2004-10-21
NO20035160D0 (no) 2003-11-20
DK1390070T3 (en) 2017-04-24
KR20040030625A (ko) 2004-04-09
AU2002314103B8 (en) 2002-12-09
SK288413B6 (sk) 2016-10-03
CN1535160A (zh) 2004-10-06
PT1390070T (pt) 2017-03-01
CZ307321B6 (cs) 2018-06-06
HUP0304067A2 (hu) 2004-03-29
UA80396C2 (en) 2007-09-25
SK16032003A3 (sk) 2004-05-04
US7655616B2 (en) 2010-02-02

Similar Documents

Publication Publication Date Title
NO20054369D0 (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
DE60211317D1 (de) Rho-kinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
DE60127098D1 (de) Inhibitoren der mucin-synthese
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
IS7678A (is) Samsetning IBAT tálma og málmsalts til að meðhöndla niðurgang
ATE333454T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
DK1485127T3 (da) Anvendelse af midler til behandling af inflammation
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
IS7792A (is) Hýdantóínafleiður og notkun þeirra sem TACE hemla
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
NO20015274L (no) ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav
EE200300452A (et) Metalloproteinaasi inhibiitorid
NO20020742L (no) Innskrenkning av innretninger for å lyddempe operasjoner
NO20042244L (no) Fenylsubstituerte triazoler og deres anvendelse som selektive inhibitorer av AKL5-kinease
NO20054837D0 (no) Formulering for inhibering av korrosjon og avleiringer
NO20041214L (no) Substituerte benzimidazolforbindelser og deres anvendelse for behandling av cancer
NO20035160L (no) Anvendelse av IL-18 inhibitorer til å behandle eller forhindre CNS-skader
NO20041938L (no) Anvendelse av fosfodiesterase IV-inhibitorer
DK1381620T3 (da) Hypersulfaterede disaccharider og fremgangsmåder til anvendelse af samme til behandling af inflammationer
AU2002211853A1 (en) Use of mek1 inhibitors as protective agents against damage due to ischemia
EE200300512A (et) Aromataasi inhibiitori kasutamine abistava reproduktsiooni suurendamiseks
NO20033125D0 (no) Anvendelse av antigestagener til inhibering av endometriummodning under infertilitetsbehandling
NO20040370L (no) Anvendelse av IL-18-inhibitorer i hypersensitivitetslidelser.

Legal Events

Date Code Title Description
MK1K Patent expired